A.G.P. is sole placement agent.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics Advances VCN-01 with FDA Guidance
- Theriva Biologics announces U.S. FDA guidance of Phase 3 study design
- Theriva Biologics Highlights Key Achievements in Q3 2024
- Theriva Biologics price target lowered to $6 from $25 at Maxim
- Theriva Biologics reports Q3 EPS ($6.81) vs. ($4.85) last year